AABB

    FDA Issues EUA for COVID-19 Convalescent Plasma; AABB Toolkit Now Available

    The Food and Drug Administration has issued an emergency use authorization (EUA) for COVID-19 convalescent plasma (CCP) as a treatment for patients battling COVID-19. AABB has developed a new toolkit for CCP under FDA’s EUA to assist members in keeping updated on the changing regulatory environment regarding CCP. AABB will update the toolkit based on additional updates. 

    Recent Stories
    AABB Releases FAQ Sheet on Blood Donation Following COVID-19 Vaccination

    AABB Extends Submission Deadline For 2021 Annual Meeting Abstracts

    Complimentary Registration Available to Science & Innovation Forum on Mitigating Bacterial Risk in Platelets